US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Amplia Therapeutics Ltd.

0.0600

0.0000

Volume:- -

Turnover:- -

Market Cap:30.78M

PE:-4.50

High:0.0600

Open:0.0600

Low:0.0600

Close:0.0600

52wk High:0.2724

52wk Low:0.0287

Shares:513.07M

Float Shares:513.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0133

EPS(LYR):-0.0133

ROE:-28.49%

ROA:-17.71%

PB:1.01

PE(LYR):-4.50

Loading ...

Overview Company News Filings

Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025

NARMAFOTINIB Large-Scale Manufactre Complete

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

Key Narmafotinib Patent Granted in the U.S.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INNMF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"INNMF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INNMF\",,,,,undefined,":{"symbol":"INNMF","market":"US","secType":"STK","nameCN":"Amplia Therapeutics Ltd.","latestPrice":0.06,"timestamp":1771880400000,"preClose":0.06,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":513000000,"shares":513071629,"eps":-0.013347,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-23 16:00:00 EST Delay","open":0.06,"high":0.06,"low":0.06,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.013347,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.06,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INNMF\",,,,,undefined,":{"symbol":"INNMF","floatShares":513000000,"roa":"-17.71%","roe":"-28.49%","lyrEps":-0.013342,"shares":513071629,"dividePrice":0,"high":0.06,"amplitude":0,"preClose":0.06,"low":0.06,"week52Low":0.0287,"pbRate":"1.01","psRate":"8.70","week52High":0.2724,"institutionHeld":0,"latestPrice":0.06,"eps":-0.013347,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.013347,"open":0.06,"prevYearClose":0.0789,"prevWeekClose":0.06,"prevMonthClose":0.1,"prevQuarterClose":0.0789,"fiveDayClose":0.0891,"twentyDayClose":0.1,"sixtyDayClose":0.0917},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INNMF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-18","symbol":"INNMF","defaultRemindTime":1713447000000,"type":"split","dateTimestamp":1713412800000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896},{"market":"US","date":"2022-05-30","symbol":"INNMF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1653883200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INNMF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INNMF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1753851600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INNMF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607004955","title":"Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2607004955","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607004955?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:45","pubTimestamp":1769780700,"startTime":"0","endTime":"0","summary":"Melbourne, Australia, Jan.  30, 2026  (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane, continues to demon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229545/0/en/Amplia-Therapeutics-Quarterly-Activities-and-Cash-Flow-Reports-December-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","LENZ","BK4139","BK4213","PR","BK4539","BK4007"],"gpt_icon":0},{"id":"2605910934","title":"NARMAFOTINIB Large-Scale Manufactre Complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910934","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910934?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:30","pubTimestamp":1769088600,"startTime":"0","endTime":"0","summary":"Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial man","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/22/3223746/0/en/NARMAFOTINIB-Large-Scale-Manufactre-Complete.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","CDMO","BK4535","BK4139","API","INNMF","BK4551","BK4503"],"gpt_icon":0},{"id":"2602054358","title":"ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054358?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225500,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216936/0/en/ACCENT-DATA-PRESENTED-AT-2026-ASCO-GASTROINTESTINAL-CANCER-SYMPOSIUM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","BK4195","BK4211","ORR","BK4139","PFS"],"gpt_icon":0},{"id":"2593413555","title":"Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413555","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593413555?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:45","pubTimestamp":1766497500,"startTime":"0","endTime":"0","summary":"Melbourne, Australia, Dec.  23, 2025  (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason Licklite","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209888/0/en/Amplia-Therapeutics-to-Present-at-2026-ASCO-Gastrointestinal-Cancers-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","INNMF","LENZ","BK4007"],"gpt_icon":0},{"id":"2592167712","title":"Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592167712","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592167712?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:45","pubTimestamp":1766151900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia’s FAK inhibitors in combination wit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208497/0/en/Amplia-Enters-into-Second-Agreement-with-Korean-Specialist-Drug-Screening-Company-Next-Bio-to-Explore-Combination-Therapy-with-FAK-Inhibitor-and-kRAS-Inhibitors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","BK4139"],"gpt_icon":0},{"id":"2590043935","title":"Additional Confirmed Response Reported as Part of Amplia Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590043935","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590043935?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547100,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Scienc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","PR","BK4213","BK4139","INNMF"],"gpt_icon":0},{"id":"2588041713","title":"Key Narmafotinib Patent Granted in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041713?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769500,"startTime":"0","endTime":"0","summary":"Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198906/0/en/Key-Narmafotinib-Patent-Granted-in-the-U-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}